US equities |
NVDA $238.37 ▲+1.89% SPCX $167.82 ▲+5.57% MU $1,063.32 ▼-1.08% TSLA $379.20 ▲+2.32% MSFT $525.03 ▲+1.45% SNDK $1,710.69 ▼-0.54% INTC $116.96 ▼-1.99% META $742.61 ▲+2.00%
FinancialContent

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

27.40 -0.27 (-0.98%)
Delayed Quote Updated: 2:16 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83... 
Via MarketMinute
Topics Earnings Economy
News headline image
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs. ↗
Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials. 
Via The Motley Fool
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗
Via Stocktwits
Why Did Structure Therapeutics Stock Surge Pre-Market Today? ↗
Via Stocktwits
News headline image
A 10% Owner Of Structure Therapeutics Shed Shares ↗
A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but that hasn't stopped the pharmaceutical stock from surging. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Can This Stock Double Again in 2026? ↗
It's a tough act to follow. 
Via The Motley Fool
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗
The development comes as attention remains on Hims’ longer-term business expansion initiatives. 
Via Stocktwits
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Case for Small-Cap Diversification: Why Investors are Looking Beyond Mega-Cap Tech
As 2025 draws to a close, the "Magnificent Seven" era of market dominance is facing its most significant challenge yet. While the first half of the year was characterized by a relentless surge in... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for... 
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Caps Seize the Spotlight as Mega-Cap Fatigue Sets In
As 2025 draws to a close, the financial landscape has undergone a seismic shift that few predicted at the start of the year. For the first time in over half a decade, the dominant narrative of "Big... 
Via MarketMinute
Topics Economy
News headline image
The Great Rotation: Small-Cap Growth Surges as Investors Ditch Defensive Safety for Post-Fed Gains
The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally.... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Rotation: Small-Caps Break Out as Russell 2000 Hits Record Highs in Late 2025
NEW YORK — In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index has finally staged its long-awaited breakout, signaling a definitive end to the years-long... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Global Markets Brace for Fed Decision Amidst Divergent Policies and Geopolitical Crosscurrents
Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
This Under-the-Radar Healthcare Stock Could Soar in 2026 ↗
We should know a lot more by year-end. 
Via The Motley Fool
News headline image
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform
Via AB Newswire
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound ↗
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >